Table 2.
Baseline and follow-up (6 weeks) clinical, ventilatory, and body fat variables in hypertensive patients (N = 52).
| Variable | Placebo | MitoQ | ET | MitoQ+ET | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
| VO2 peak (ml/min) | NA | NA | NA | NA | 3120 ± 138 | NA | 3030 ± 139 | NA |
| VE/VO2 | NA | NA | NA | NA | 30.5 ± 0.83 | NA | 29.7 ± 0.83 | NA |
| VE/VCO2 | NA | NA | NA | NA | 29.8 ± 0.56 | NA | 29.1 ± 0.57 | NA |
| RER | NA | NA | NA | NA | 1.02 ± 0.02 | NA | 1.01 ± 0.02 | NA |
| Abdominal fat (mm) | 32.5 ± 1.0 | 32.8 ± 1.2 | 33.2 ± 1.5 | 30.6 ± 1.2∗ | 37.5 ± 2.4 | 34.8 ± 2.2∗ | 39.8 ± 1.3 | 36.2 ± 1.3∗∗∗### |
| Supraspinal fat (mm) | 27.7 ± 1.0 | 27.8 ± 1.2 | 29.0 ± 1.2 | 27.2 ± 1.4∗ | 27.9 ± 1.4 | 25.5 ± 1.6∗∗∗ | 32.9 ± 2 | 30.3 ± 1.7∗∗∗###δδδ |
| Breast fat (mm) | 22.8 ± 0.8 | 22.9 ± 1.1 | 24.7 ± 0.8 | 24.2 ± 0.5 | 27.4 ± 0.8 | 26.2 ± 0.9 | 27.4 ± 0.8 | 27 ± 0.8### |
| Triceps fat (mm) | 20.6 ± 0.7 | 20.8 ± 0.7 | 20.6 ± 0.7 | 19.4 ± 0.8 | 24.2 ± 0.6 | 23.3 ± 0.6 | 24.3 ± 0.9 | 23.3 ± 1.1### |
| Subscapular fat (mm) | 23.4 ± 0.7 | 23.5 ± 0.8 | 22.2 ± 0.8 | 23.1 ± 0.8 | 24.5 ± 0.8 | 23.4 ± 0.7 | 25.3 ± 1.0 | 24.8 ± 1.1##δ |
| Calf fat (mm) | 4.8 ± 0.7 | 4.7 ± 0.6 | 5.0 ± 0.5 | 4.8 ± 0.5 | 6.5 ± 0.8 | 5.9 ± 0.7 | 7.3 ± 0.7 | 6.6 ± 0.5### |
| Thigh fat (mm) | 13.8 ± 0.28 | 13.9 ± 0.26 | 14.1 ± 0.45 | 13.8 ± 0.39 | 14.5 ± 0.47 | 14.2 ± 0.40 | 15.5 ± 0.43 | 15.4 ± 0.48 |
| Body fat (%) | 23.3 ± 0.7 | 23.4 ± 0.8 | 23.9 ± 0.8 | 23.2 ± 0.6 | 25.1 ± 0.7 | 23.7 ± 0.7∗ | 26.4 ± 0.8 | 24.9 ± 0.7∗ |
The data are expressed as mean ± SEM. ∗Significantly vs. baseline, #significantly vs. MitoQ follow-up, δsignificantly vs. ET follow-up. ET: endurance training, HR: heart rate, RER: respiratory exchange ratio, NA: not applicable.